Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Plasminogen activators (PAs) are not used for thromboprophylaxis due to rapid clearance, bleeding, and extravascular toxicity. We describe a novel strategy that overcomes these limitations. We conjugated tissue-type PA (tPA) to a monoclonal antibody (mAb) against complement receptor type 1 (CR1) expressed primarily on human RBCs. Anti-CR1/tPA conjugate, but not control conjugate (mIgG/tPA), bound to human RBCs (1.2 x 10(3) tPA molecules/cell at saturation), endowing them with fibrinolytic activity. In vitro, RBC-bound anti-CR1/tPA caused 90% clot lysis versus 20% by naive RBCs. In vivo, more than 40% of anti-CR1/(125)I-tPA remained within the circulation ( approximately 90% bound to RBCs) 3 hours after injection in transgenic mice expressing human CR1 (TgN-hCR1) versus less than 10% in wild-type (WT) mice, without RBC damage; approximately 90% of mIgG/(125)I-tPA was cleared from the circulation within 30 minutes in both WT and TgN-hCR1 mice. Anti-CR1/tPA accelerated lysis of pulmonary emboli and prevented stable occlusive carotid arterial thrombi from forming after injection in TgN-hCR1 mice, but not in WT mice, whereas soluble tPA and mIgG/tPA were ineffective. Anti-CR1/tPA caused 20-fold less rebleeding in TgN-hCR1 mice than the same dose of tPA. CR1-directed immunotargeting of PAs to circulating RBCs provides a safe and practical means to deliver fibrinolytics for thromboprophylaxis in settings characterized by a high imminent risk of thrombosis.

[1]  M. Magnani,et al.  Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides , 2002, Gene Therapy.

[2]  E. Braunwald,et al.  Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction , 2000, Journal of clinical pharmacology.

[3]  B. Ru,et al.  Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase. , 2001, Biochimie.

[4]  W. Scheld,et al.  Cross‐linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys , 1994, European journal of immunology.

[5]  E. Haber,et al.  Antibody-directed urokinase: a specific fibrinolytic agent. , 1985, Science.

[6]  W. Krupski,et al.  Antithrombotic therapy in peripheral arterial occlusive disease. , 1998, Chest.

[7]  J. Loscalzo,et al.  Platelet-monocyte aggregates: bridging thrombosis and inflammation. , 2002, Circulation.

[8]  E. Yeh,et al.  A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. , 1997, Circulation.

[9]  P. Carmeliet,et al.  Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. , 1998, Circulation.

[10]  R. Nagel,et al.  Molecular cloning and expression of a chloride channel-associated protein pICln in human young red blood cells: association with actin. , 1997, The Biochemical journal.

[11]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[12]  Sidney Strickland,et al.  Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator , 1995, Nature.

[13]  V. Muzykantov,et al.  Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. , 1996, Analytical biochemistry.

[14]  J. Atkinson,et al.  Structure–function relationships of complement receptor type 1 , 2001, Immunological reviews.

[15]  D. Eslin,et al.  Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. , 2003, Blood.

[16]  M. Little,et al.  Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. , 2000, Circulation.

[17]  M. Kuo,et al.  Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[19]  V. Muzykantov,et al.  Platelets inhibit the lysis of pulmonary microemboli. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[20]  T. W. Love,et al.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Antman,et al.  Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. , 2005, Circulation.

[22]  S. Johnston.  Clinical practice. Transient ischemic attack. , 2002, The New England journal of medicine.

[23]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[24]  J. Bradberry.  Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy. , 2004, Journal of the American Pharmacists Association : JAPhA.

[25]  Vladimir R Muzykantov,et al.  Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  V. Marder,et al.  Thrombolytic therapy: 2001. , 2001, Blood reviews.

[27]  J. Goldstein,et al.  Design and evaluation of a thrombin-activable plasminogen activator. , 1994, Biochemistry.

[28]  K. Ouriel,et al.  Invasive approaches to treatment of venous thromboembolism. , 2004, Circulation.

[29]  S. Jones,et al.  A transgenic mouse model for studying the clearance of blood‐borne pathogens via human complement receptor 1 (CR1) , 2005, Clinical and experimental immunology.

[30]  G. FitzGerald,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[31]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[32]  D. Dichek,et al.  Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. , 1996, Circulation.

[33]  C. Bode,et al.  Construction and characterization of a recombinant plasminogen activator composed of an anti‐fibrin single‐chain antibody and low‐molecular‐weight urokinase , 2004, Journal of thrombosis and haemostasis : JTH.

[34]  E. Mulvihill,et al.  Fibrin Affinity and Clearance of t-PA Deletion and Substitution Analogues , 1990, Thrombosis and Haemostasis.

[35]  E. Ohtsuka,et al.  Detailed study of sequence-specific DNA cleavage of triplex-forming oligonucleotides linked to 1,10-phenanthroline. , 1994, Biochemistry.

[36]  R. Califf,et al.  Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. , 2004, The American journal of medicine.

[37]  C. Hahn,et al.  Heteropolymer‐mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications , 2001, Immunological reviews.

[38]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[39]  E. L. Wright,et al.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Houng,et al.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Furie,et al.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.

[42]  H. Lijnen,et al.  Novel thrombolytic agents , 1994, Cardiovascular Drugs and Therapy.

[43]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[44]  D. Dichek,et al.  Gene therapy for arterial thrombosis. , 1997, Cardiovascular research.

[45]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[46]  V. Muzykantov,et al.  Urokinase mediates fibrinolysis in the pulmonary microvasculature. , 2000, Blood.

[47]  Atkinson,et al.  Mapping epitopes for 20 monoclonal antibodies to CR1 , 1998, Clinical and experimental immunology.

[48]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[49]  D. Fearon.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte , 1980, The Journal of experimental medicine.

[50]  B. Keyt,et al.  Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog , 1994, Thrombosis and Haemostasis.

[51]  D. Cafiso,et al.  Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys. , 1995, Journal of immunology.

[52]  J. Seidman,et al.  Construction and expression of a recombinant antibody-targeted plasminogen activator. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Johnston,et al.  Transient Ischemic Attack , 2002 .

[54]  S. Snapinn,et al.  Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and s , 1999, Circulation.

[55]  B. Keyt,et al.  New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.

[56]  W. Weaver,et al.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.

[57]  D. Birmingham,et al.  CR1 and CR1‐like: the primate immune adherence receptors , 2001, Immunological reviews.

[58]  A. J. White,et al.  Glycoprotein IIb/IIIa Receptor Antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-{[2-({4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl}amino)acetyl]amino}propanoic Acid Dihydrochloride (CRL42796), in Combination with Aspirin and/or Enoxaparin, Prevents Coronary Artery Rethrombosis after Success , 2003, Journal of Pharmacology and Experimental Therapeutics.

[59]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. , 1993, The Journal of clinical investigation.

[60]  G. Matthyssens,et al.  Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. , 1993, Blood.

[61]  A. Rebuzzi,et al.  Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. , 1997, Circulation.

[62]  D. Rijken,et al.  Superficial accumulation of plasminogen during plasma clot lysis. , 1995, Circulation.

[63]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.